Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Akin

Showing results (141-150 of 203) with videos related to

Pageof 21
Sort By:
Leukemia & Lymphoma|December 29, 2004
Mastocytosis: pathology, genetics, and current options for therapyPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 5, 2024
The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease ControlFrank Siebenhaar, Senan Sofi, Sophia Neisinger, et al.
The Journal of Allergy and Clinical Immunology|November 28, 2020
Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphologyMatthew P Giannetti, Cem Akin, Raied Hufdhi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 24, 2025
Continued symptom and quality of life improvement with favorable safety shown with long-term avapritinib in indolent systemic mastocytosisMariana Castells, Cem Akin, Karin Hartmann, et al.
International Journal of Molecular Sciences|December 2, 2020
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized MedicinePeter Valent, Cem Akin, Boguslaw Nedoszytko, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
Blood|August 7, 2010
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD)Peter Valent, Michel Arock, Cem Akin, et al.
Haematologica|January 2, 2008
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusionIdoya Lahortiga, Cem Akin, Jan Cools, et al.
International Journal of Molecular Sciences|October 28, 2023
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel ConceptsPeter Valent, Cem Akin, Michel Arock, et al.
The Journal of Allergy and Clinical Immunology|August 13, 2021
Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: A Work Group Report of the AAAAI Allergic Skin Diseases CommitteeNives Zimmermann, J Pablo Abonia, Stephen C Dreskin, et al.
Pageof 21

Showing results (141-150 of 203) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|December 29, 2004
Mastocytosis: pathology, genetics, and current options for therapyPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 5, 2024
The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease ControlFrank Siebenhaar, Senan Sofi, Sophia Neisinger, et al.
The Journal of Allergy and Clinical Immunology|November 28, 2020
Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphologyMatthew P Giannetti, Cem Akin, Raied Hufdhi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 24, 2025
Continued symptom and quality of life improvement with favorable safety shown with long-term avapritinib in indolent systemic mastocytosisMariana Castells, Cem Akin, Karin Hartmann, et al.
International Journal of Molecular Sciences|December 2, 2020
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized MedicinePeter Valent, Cem Akin, Boguslaw Nedoszytko, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
Blood|August 7, 2010
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD)Peter Valent, Michel Arock, Cem Akin, et al.
Haematologica|January 2, 2008
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusionIdoya Lahortiga, Cem Akin, Jan Cools, et al.
International Journal of Molecular Sciences|October 28, 2023
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel ConceptsPeter Valent, Cem Akin, Michel Arock, et al.
The Journal of Allergy and Clinical Immunology|August 13, 2021
Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: A Work Group Report of the AAAAI Allergic Skin Diseases CommitteeNives Zimmermann, J Pablo Abonia, Stephen C Dreskin, et al.
Pageof 21